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Abstract. Heart Failure (HF) is a clinical syndrome characterised by signs of systemic and 
pulmonary fluid retention, shortness of breath and/or fatigue. There is a lack of reliable 
indicators of disease state. Benefits and applicability of non-invasive bioimpedance 
measurement in the hydration state of soft tissues have been validated, fundamentally, in 
dialysis patients. Four impedance configurations (2 longitudinal and 2 transversal) were 
analyzed in 48 HF patients (M=28, F=20) classified according to a clinical disease severity 
score (CDSS) derived from the Framingham criteria: CDSS?2 (G1: M= 23, F= 14) and 
CDSS>2 (G2: M= 5, F= 6). The aim of this study is to analyze longitudinal and transversal 
bioimpedance measurement at 50 kHz, in addition to clinical diagnosis parameters of heart 
failure, including: clinical disease severity score (CDSS) and a biomarker concentrations (NT-
proBNP). The Kolmogorov-Smirnov test was used for the normality test of all variables. The 
CDSS, NTproBNP and impedance parameters between groups (G1 and G2) were compared by 
mean of Mann Withney U-test. The statistical significance was considered with P < 0.05. 
Whole-body impedance measured was analyzed using RXc graph.  
1. Introduction 
Heart failure (HF) is a clinical syndrome defined by the inability of the heart to provide adequate 
blood flow to other organs. Consequently, it generates systemic and pulmonary fluid retention. This 
congestion is the responsible of the symptoms (breathlessness, fatigue, anorexia) and signs (peripheral 
oedema, hepatomegaly, rales over lungs) that are used in the diagnosis of the exacerbation of HF. 
However, their lack of sensitivity and the importance to detect congestion in early stages supports the 
need of more aggressive management of these patients. For this reason, biomarkers concentration, 
particularly B-type natriuretic peptide (BNP) and its amino-terminal cleavage equivalent (NT-
proBNP) [1] helps to the clinical features in the diagnosis of the syndrome. However, they also have a 
significant heterogeneity, and better markers are needed. The feasibility of segmental bioimpedance 
measurement [5] in the determination of segmental volumes and regional fluid shifts to overcome the 
limitations of whole-body impedance methods is an alternative. 
The bioelectrical impedance vector analysis BIVA [2] is a non invasive procedure easily applicable in 
the clinic due to its sensitivity to detect changes in the hydration of soft tissues. This method is 
unaffected by regression adjustments to estimate body composition, body geometry or hydration state. 
The aim of this study is to analyze longitudinal and transversal bioimpedance measurement at 50 kHz, 
in addition to clinical diagnosis parameters of heart failure. 
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2. Methods 
2.1 Patients 
Patient clinical status, NT-proBNP levels and bioimpedance measurements were obtained from 48 
patients (M= 28; F= 20). The study was approved by the Local Ethics Committee and informed 
consent was obtained from each patient. Exclusion criteria included the presence of: 1) pacemaker or 
implantable automatic defibrillator; 2) large metallic prosthesis such as hip or knee prosthesis; and 3) 
limb amputations. HF clinical disease severity score (CDSS) based on Framingham criteria was used 
to diagnose destabilized HF. Two groups of patients were identified based on clinical criteria: group 
G1 of stable HF patients with CDSS ? 2, and group G2 of non-stable congestive HF patients with 
CDSS > 2. NT-proBNP levels were measured by electrochemiluminescence immunoassay using 
Elecsys 1010 analyzer (Roche Diagnostics GmbH, Mannheim, Germany). 
2.2 Bioimpedance Measurements 
Impedance measurements were taken with model SFB7 (ImpediMed, Queensland, Australia) at 50 
kHz with injected current of 800 μA. The specific measurement error of the system is lower than 1 ? 
and 1 ? at 50 kHz using electrical models. Tetrapolar bioimpedance measurements were made in four 
electrode configurations: whole-body (RS), longitudinal leg (LLEG), transversal bioimpedance 
measurement in cross-section of the right hemithorax (TTH), and transversal bioimpedance 
measurement in cross-section of the hepatic abdominal region (TAB). Disposable pre-gelled Ag/AgCl 
(3M Red Dot, Canada) electrodes were used. 
 
 
Figure 1. Electrode locations for longitudinal measurements:  whole-body (a), longitudinal 
leg (b). Transversal measurements location: cross-section of the right hemithorax (c), cross-
section of the hepatic abdominal region (d).  Electrode locations for transversal 
measurements (e). 
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2.3 Statistical Methods 
Forty-eight HF patients were identified in two groups of patients based on clinical criteria: group G1 
of stable HF patients with CDSS ? 2, and group G2 of non-stable congestive HF patients with CDSS > 
2. All data are expressed as mean values (± SD). Individual bioelectrical impedance vector, in whole-
body (RS) was analysed in the RXc-graph [2] with tolerance ellipses (50%, 75% and 95%) of the 
reference population [3]. Whole-body (RS) impedance measured was normalized by height of the 
patients (H), longitudinal leg (LLEG) by leg length (LL); transversal bioimpedance measurement in 
cross-section of the right hemithorax (TTH) by perimeter of the thorax (PT); and finally transversal 
bioimpedance measurement in cross-section of the hepatic abdominal region (TAB) by abdominal 
circumference (AC). Kolmogorov-Smirnov test was used for the normality test of clinical, laboratory 
and bioimpedance vector components. For differences between impedance vector components with 
clinical and laboratory parameters the Mann-Whitney test was used. Minitab software version 15.1.0 
(Minitab, Inc.) was used for statistical analysis. Statistical significance was considered with p < 0.05.   
3. Results 
Table 1 and table 2 show the mean ± standard deviation (SD) of CDSS, NTproBNP, impedance 
parameters (R and Xc), and Mann Whitney-U test, for male and female sample.  
 
 
Table 1. Clinical and impedance parameters in male sample 
 G1 (CDSS ? 2) 
N=23 
G2 (CDSS > 2) 
N=5 
P 
CDSS          1.0 ± 0.5 3.3 ± 1.1 0.000** 
NTpro BNP 2777 ± 3441 2936 ± 2380 0.589 
RS, R/H 
RS, Xc/H  
304.5 ± 63.0
25.5 ± 5.7
247.9 ± 50.9 
19.6 ± 6.9
0.081 
0.047* 
LLEG, R/LL 
LLEG, Xc/LL 
TTH, R/PT 
TTH, Xc/PT 
398.0 ± 98.0 
30.5 ± 13.8 
42.3 ± 10.4 
4.7 ± 1.8
237.1 ± 48.5 
11.8 ± 3.8 
31.9 ± 14.2 
4.1 ± 1.6
0.004* 
0.005* 
0.093 
0.435 
TAB, R/AC 44.8 ± 13.2 32.9 ± 13.1 0.150 
TAB, Xc/AC 4.6 ± 1.7 3.4 ± 0.5 0.026* 
Table 2. Clinical and impedance parameters in female sample 
 G1 (CDSS ? 2) 
N=14 
G2 (CDSS > 2) 
N=6 
P 
CDSS          1.4 ± 0.4 3.1 ± 1.0 0.000** 
NTpro BNP 3317 ± 3416 665 ± 167 0.107 
RS, R/H 
RS, Xc/H  
322.2 ± 82.1
25.2 ± 7.0
320.5 ± 68.8 
28.4 ± 7.8
1.000 
0.713 
L-LEG, R/LL 
L-LEG, Xc/LL 
T-TH, R/PT 
T-TH, Xc/PT 
360.9 ± 115.5 
23.0 ± 9.5 
46.6± 12.6 
4.8 ± 0.9
396.2 ± 144.5 
30.0 ± 17.6 
42.2 ± 8.9 
5.3 ± 0.9
0.386 
0.302 
0.386 
0.231 
T-AB, R/AC 53.0 ± 19.2 50.8 ± 12.9 0.836 
T-AB, Xc/AC 4.9 ± 1.0 4.8 ± 2.3 0.483 
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Figure 2. Individual vectors for 48 patients with CDSS?2 (G1: M= 23, F= 14) and 
with CDSS>2 (G2: M= 5, F= 6) in the tolerance ellipses for the reference 
population [3]. 
 
4. Discussion and Conclusions 
The Mann-Whitney U test results in the male sample (table 1) indicate a statistically significant 
difference in R and Xc parameters in the L-LEG segment; and Xc parameters in the T-AB and RS 
segment. In BIVA, R/H provides information of the hydration state and Xc/H the structure of soft 
tissues. In some previous studies, the inferior pole of the 75% tolerance ellipse was considered the 
threshold for oedema [4]. Figure 2 shows individual impedance vector in RS configuration. Some 
patients classified as G1 with CDSS ? 2 were located by BIVA in the hyper-hydration region; and 
some patients classified as G2 with CDSS ? 2 were located in the normal-hydration region in males 
and more prominent in female’s sample. This situation and the small sample size might be the reason 
why the table 2 not shows statistically significant results in any segment. Patterson et al 1988 analyzed 
the feasibility of segmental bioimpedance measurement in the determination of segmental volumes 
and regional fluid shifts to overcome the limitations of whole-body (RS) impedance methods. This 
preliminary study suggests that in HF longitudinal bioimpedance measurement in leg segment (L-
LEG) provides additional information to clinical examination and could even reflect sub-clinical 
hyper-hydration. 
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